CHWY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chewy is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has meaningful long-term operating improvements and analysts remain broadly positive, but the current price action is weak, insider/hedge fund selling is heavy, and there is no proprietary buy signal today. My direct view: hold and wait for a cleaner entry rather than buying now.
CHWY is in a short-term downtrend. MACD histogram is -0.415 and still weakening, RSI_6 at 16.819 shows the stock is deeply oversold, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 21.57 is near support at 21.688 and above S2 at 20.534, so downside may be somewhat limited near term, but the trend is still negative. The setup looks oversold, not confirmed bullish.
Chewy continues to gain market share, and recent analyst commentary highlights better-than-feared earnings, stronger-than-expected FY2026 guidance, and improving margin expansion. The company is targeting adjusted EBITDA margin improvement from 5.7% to 10%, which is a meaningful long-term catalyst. News also points to growing active customers, Autoship penetration, Chewy Vet Care traction, and AI-driven SG&A savings. Recent analyst targets remain mostly supportive, with several Buy/Outperform ratings and targets in the $37-$49 range.
Hedge funds are selling heavily, with selling up 382.78% last quarter, and insiders are also selling sharply, up 2640.37% over the last month. The latest news summary notes retail sector challenges and specifically says analysts are refraining from recommending Chewy right now. Price action remains weak, and the stock is trading far below many analysts' targets. No AI Stock Picker or SwingMax signal is present today, removing a strong timing catalyst.
Latest financial snapshot was not available due to an error, but the recent reported trend is still constructive. News says fiscal 2025 net sales grew 6% to $12.6B, and operating income surged 125%, showing clear profitability improvement. Recent analyst notes also cite Q4 revenue of $3.27B above the high end of guidance and FY2026 outlook that was ahead of expectations. Overall, the latest quarter season appears to be Q4 with solid revenue growth and improving margins.
Analyst sentiment is still mostly positive, but price targets have been trimmed recently. Citi cut its target to $37 from $40 while keeping Buy, Morgan Stanley lowered to $49 from $50 and kept Overweight, RBC raised to $47, Goldman cut to $46 but kept Buy, TD Cowen raised to $42, and UBS is the notable Neutral at $32. Wall Street pros see the bullish case in share gains, margin expansion, and guidance strength; the bear case is valuation pressure, retail-sector concerns, and some weakening forward demand caution. Overall, the analyst view is constructive but not aggressive enough to make this a clear buy at the current price.
